Corona Remedies IPO Subscription Status

Corona Remedies IPO subscription started on 8 December, 2025 and will close on 10 December, 2025. The retail quota is 35%, QIB is 50% and NII is 15%. Corona Remedies IPO got a lot of interest, raising around ₹61,71,101 shares (aggregating up to ₹655.37 Cr) Crores, with subscriptions 144.49 times overall, including 293.8 times by institutional investors, 220.18 times by non-institutional investors, and 30.29 times by retail investors. Shares are priced between ₹₹1008 to ₹1062 per share each and will be listed on the BSE and NSE.
  Check Live IPO  Subscription List  👈
Listed
Last Updated - December 10, 2025 11:55 pm

Corona Remedies IPO Subscription - Day 3

QIB - Qualified Institutional Buyers: 293.8x
NII - Non-Institutional Investors: 220.18x
SNII - Small Non-Institutional Investors: 167.2x
BNII - Big Non-Institutional Investors: 246.67x
RII - Retail Individual Investor: 30.29x
Total: 144.49x 👈

Corona Remedies IPO Investor Categories

  • Qualified Institutional Buyers: QIB
  • Non-Institutional Investors: NII
  • Small Non-Institutional Investors: SNII- Bid below ₹10L
  • Big Non-Institutional Investors: BNII- Bid above ₹10L
  • Retail Individual Investor: RII
  • Employees Quota: EMP

Corona Remedies IPO Dates

IPO Activity Date
Open Date: 8 December, 2025
Close Date: 10 December, 2025
Allotment Date: 11 December, 2025
Refund Date: 12 December, 2025
Shares Credit Date: 12 December, 2025
Listing Date: 15 December, 2025

Corona Remedies IPO Subscription Status FAQs

Q.When Corona Remedies IPO Subscription will start?

Ans.The IPO subscription starts on 8 December, 2025 for Investors.


Q.What is the Corona Remedies IPO Subscription last date?

Ans.Corona Remedies IPO subscription last date is 10 December, 2025 for Investors.


Q.What is the Corona Remedies IPO Allotment Date?

Ans.Corona Remedies IPO allotment date is 11 December, 2025.


Q.What is the Corona Remedies IPO Listing Date?

Ans.Corona Remedies IPO listing date is 15 December, 2025. The IPO is to list on BSE and NSE.